annual EBITDA:
-$504.55M+$11.91M(+2.31%)Summary
- As of today (September 16, 2025), RARE annual EBITDA is -$504.55 million, with the most recent change of +$11.91 million (+2.31%) on December 31, 2024.
- During the last 3 years, RARE annual EBITDA has fallen by -$94.22 million (-22.96%).
- RARE annual EBITDA is now -7608.86% below its all-time high of -$6.54 million, reached on December 31, 2011.
Performance
RARE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$99.27M+$34.68M(+25.89%)Summary
- As of today (September 16, 2025), RARE quarterly EBITDA is -$99.27 million, with the most recent change of +$34.68 million (+25.89%) on June 30, 2025.
- Over the past year, RARE quarterly EBITDA has increased by +$8.23 million (+7.66%).
- RARE quarterly EBITDA is now -96477.67% below its all-time high of $103.00 thousand, reached on June 30, 2013.
Performance
RARE quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$469.65M+$8.23M(+1.72%)Summary
- As of today (September 16, 2025), RARE TTM EBITDA is -$469.65 million, with the most recent change of +$8.23 million (+1.72%) on June 30, 2025.
- Over the past year, RARE TTM EBITDA has increased by +$46.09 million (+8.94%).
- RARE TTM EBITDA is now -10219.64% below its all-time high of -$4.55 million, reached on September 1, 2012.
Performance
RARE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RARE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.3% | +7.7% | +8.9% |
| 3 y3 years | -23.0% | +27.6% | -3.1% |
| 5 y5 years | -29.4% | -65.8% | -21.7% |
RARE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -23.0% | +21.2% | at high | +55.0% | -3.1% | +27.9% |
| 5 y | 5-year | -260.9% | +21.2% | -110.2% | +55.0% | -61.9% | +27.9% |
| alltime | all time | -7608.9% | +21.2% | <-9999.0% | +55.0% | <-9999.0% | +27.9% |
RARE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$99.27M(-25.9%) | -$469.65M(-1.7%) |
| Mar 2025 | - | -$133.95M(+18.3%) | -$477.88M(-4.5%) |
| Dec 2024 | -$504.55M(-2.3%) | -$113.20M(-8.1%) | -$500.43M(-0.1%) |
| Sep 2024 | - | -$123.23M(+14.6%) | -$501.06M(-2.8%) |
| Jun 2024 | - | -$107.50M(-31.3%) | -$515.74M(-6.3%) |
| Mar 2024 | - | -$156.50M(+37.5%) | -$550.13M(+1.4%) |
| Dec 2023 | -$516.45M(-19.4%) | -$113.83M(-17.5%) | -$542.50M(-4.7%) |
| Sep 2023 | - | -$137.91M(-2.8%) | -$569.34M(-12.7%) |
| Jun 2023 | - | -$141.90M(-4.7%) | -$651.81M(+0.7%) |
| Mar 2023 | - | -$148.87M(+5.8%) | -$647.02M(+2.6%) |
| Dec 2022 | -$640.49M(+56.1%) | -$140.67M(-36.2%) | -$630.70M(+7.1%) |
| Sep 2022 | - | -$220.37M(+60.7%) | -$589.06M(+29.4%) |
| Jun 2022 | - | -$137.11M(+3.4%) | -$455.30M(+14.4%) |
| Mar 2022 | - | -$132.54M(+33.8%) | -$397.84M(+8.0%) |
| Dec 2021 | -$410.32M(+193.5%) | -$99.03M(+14.3%) | -$368.50M(+5.5%) |
| Sep 2021 | - | -$86.61M(+8.7%) | -$349.22M(+12.7%) |
| Jun 2021 | - | -$79.66M(-22.8%) | -$309.83M(+6.8%) |
| Mar 2021 | - | -$103.20M(+29.4%) | -$290.04M(-4.8%) |
| Dec 2020 | -$139.81M(-64.1%) | -$79.75M(+68.9%) | -$304.65M(-4.0%) |
| Sep 2020 | - | -$47.22M(-21.1%) | -$317.19M(-17.8%) |
| Jun 2020 | - | -$59.87M(-49.2%) | -$385.86M(-11.6%) |
| Mar 2020 | - | -$117.81M(+27.7%) | -$436.35M(+5.0%) |
| Dec 2019 | -$389.77M(+119.5%) | -$92.28M(-20.4%) | -$415.63M(+1.2%) |
| Sep 2019 | - | -$115.89M(+5.0%) | -$410.75M(+8.0%) |
| Jun 2019 | - | -$110.37M(+13.7%) | -$380.15M(+6.0%) |
| Mar 2019 | - | -$97.09M(+11.1%) | -$358.60M(+1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$177.56M(-43.2%) | -$87.40M(+2.5%) | -$351.83M(-0.3%) |
| Sep 2018 | - | -$85.29M(-4.0%) | -$352.76M(+0.8%) |
| Jun 2018 | - | -$88.82M(-1.7%) | -$350.08M(+3.4%) |
| Mar 2018 | - | -$90.33M(+2.3%) | -$338.65M(+6.8%) |
| Dec 2017 | -$312.51M(+27.8%) | -$88.32M(+6.9%) | -$317.12M(+6.3%) |
| Sep 2017 | - | -$82.62M(+6.8%) | -$298.19M(+6.4%) |
| Jun 2017 | - | -$77.39M(+12.5%) | -$280.32M(+7.7%) |
| Mar 2017 | - | -$68.79M(-0.9%) | -$260.30M(+6.4%) |
| Dec 2016 | -$244.58M(+67.1%) | -$69.39M(+7.2%) | -$244.58M(+5.9%) |
| Sep 2016 | - | -$64.75M(+12.9%) | -$230.87M(+12.3%) |
| Jun 2016 | - | -$57.36M(+8.1%) | -$205.61M(+15.4%) |
| Mar 2016 | - | -$53.08M(-4.7%) | -$178.13M(+21.7%) |
| Dec 2015 | -$146.35M(+160.9%) | -$55.68M(+41.0%) | -$146.35M(+36.3%) |
| Sep 2015 | - | -$39.49M(+32.2%) | -$107.41M(+28.5%) |
| Jun 2015 | - | -$29.88M(+40.3%) | -$83.55M(+24.4%) |
| Mar 2015 | - | -$21.30M(+27.3%) | -$67.17M(+19.8%) |
| Dec 2014 | -$56.09M(+76.2%) | -$16.73M(+7.0%) | -$56.09M(+15.0%) |
| Sep 2014 | - | -$15.64M(+15.9%) | -$48.78M(+19.6%) |
| Jun 2014 | - | -$13.50M(+32.1%) | -$40.79M(+50.0%) |
| Mar 2014 | - | -$10.22M(+8.6%) | -$27.19M(+15.3%) |
| Dec 2013 | -$31.84M(+103.1%) | -$9.41M(+22.9%) | -$23.59M(+25.7%) |
| Sep 2013 | - | -$7.66M(-7533.0%) | -$18.76M(+19.8%) |
| Jun 2013 | - | $103.00K(-101.6%) | -$15.66M(-0.7%) |
| Mar 2013 | - | -$6.62M(+44.4%) | -$15.76M(+72.5%) |
| Dec 2012 | -$15.67M(+139.4%) | -$4.59M(+0.8%) | -$9.14M(+100.8%) |
| Sep 2012 | - | -$4.55M | -$4.55M |
| Dec 2011 | -$6.54M | - | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual EBITDA?
- What is the all time high annual EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. TTM EBITDA year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual EBITDA?
The current annual EBITDA of RARE is -$504.55M
What is the all time high annual EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual EBITDA is -$6.54M
What is Ultragenyx Pharmaceutical Inc. annual EBITDA year-on-year change?
Over the past year, RARE annual EBITDA has changed by +$11.91M (+2.31%)
What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA?
The current quarterly EBITDA of RARE is -$99.27M
What is the all time high quarterly EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly EBITDA is $103.00K
What is Ultragenyx Pharmaceutical Inc. quarterly EBITDA year-on-year change?
Over the past year, RARE quarterly EBITDA has changed by +$8.23M (+7.66%)
What is Ultragenyx Pharmaceutical Inc. TTM EBITDA?
The current TTM EBITDA of RARE is -$469.65M
What is the all time high TTM EBITDA for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high TTM EBITDA is -$4.55M
What is Ultragenyx Pharmaceutical Inc. TTM EBITDA year-on-year change?
Over the past year, RARE TTM EBITDA has changed by +$46.09M (+8.94%)